Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells. Combining a radiolabeled monoclonal antibody with autologous stem cell transplantation may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of combining iodine I 131 tositumomab with autologous stem cell transplantation in treating older patients who have relapsed or refractory non-Hodgkin's lymphoma.
Key facts
- Study ID
- NCT00073931
- Run by
- Fred Hutchinson Cancer Center
- People needed
- 25
- Starts
- 1999-10-01
- Expected to finish
- 2014-07-01
- Last updated by the study team
- 2015-02-05
Who can join
Age: 60 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.